Treace to Report First Quarter 2026 Financial Results on May 8, 2026
Rhea-AI Summary
Treace Medical Concepts (NasdaqGS: TMCI) will report first quarter 2026 financial results before market open on May 8, 2026. Management will host a conference call at 8:00 AM ET the same day. A live and archived webcast will be available on the company investor relations website.
Investors must register to receive dial-in numbers and a unique PIN to join and ask questions.
Positive
- None.
Negative
- None.
News Market Reaction – TMCI
In the Apr 24 session, TMCI gained 8.79%, reflecting a notable positive market reaction. Argus tracked a peak move of +4.2% during that session. Our momentum scanner triggered 15 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 07 | Product launch update | Positive | -6.9% | Announced first surgical cases using new SuperBite Compression Screw System. |
| Feb 27 | Earnings results | Neutral | -11.4% | Reported Q4 and full-year 2025 results and issued 2026 financial guidance. |
| Feb 24 | Clinical data update | Positive | -2.0% | Highlighted positive interim clinical data and new product innovations at ACFAS. |
| Feb 12 | Earnings date change | Neutral | -2.1% | Updated the scheduled date for Q4 and full-year 2025 earnings release. |
| Jan 13 | Preliminary revenue | Neutral | -3.2% | Issued preliminary, unaudited Q4 and full-year 2025 revenue ranges. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent announcements—product launches, clinical updates, earnings and prelims—have often been followed by negative 24-hour price reactions despite generally constructive content.
Over the past several months, Treace has reported preliminary 2025 revenue ranges, detailed full-year 2025 results with revenue of $212.7M and an adjusted EBITDA loss of $3.9M, and provided 2026 guidance of $200M–$212M in revenue with a planned $4M–$6M adjusted EBITDA loss. The company also highlighted positive clinical data and new systems, plus the SuperBite™ launch targeting an added $300M market. Despite this, each of these events saw negative next-day moves, framing today’s simple earnings-date notice against a backdrop of cautious trading.
AI-generated analysis. How Rhea-AI works. Not financial advice.
PONTE VEDRA, Fla., April 24, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced that it will release financial results for the first quarter 2026 before the start of trading on Friday, May 8, 2026. Company management will host a conference call to discuss financial results beginning at 8:00 am ET.
Investors interested in listening to the conference call may do so by registering. Once registered, participants will receive dial-in numbers and a unique pin to join the call and ask questions. A live and archived webcast of the event will be available on the Company’s investor relations website at https://investors.treace.com/.
Internet Posting of Information
Treace routinely posts information that may be important to investors in the “Investor Relations” section of its website at www.treace.com. The Company encourages investors and potential investors to consult the Treace website regularly for important information about Treace.
About Treace Medical Concepts
Treace Medical Concepts, Inc. is a medical technology company with the goal of advancing the standard of care for the surgical management of bunion and related midfoot deformities. Bunions are complex 3-dimensional deformities that originate from an unstable joint in the middle of the foot and affect approximately 67 million Americans, of which Treace estimates 1.1 million are annual surgical candidates. Treace has pioneered and patented the Lapiplasty®3D Bunion Correction® System – a combination of instruments, implants, and surgical methods designed to surgically correct all three planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion and helping patients get back to their active lifestyles. To further support the needs of surgeons and bunion patients, Treace offers its Adductoplasty® Midfoot Correction System, designed for reproducible surgical correction of midfoot deformities, two systems for minimally invasive osteotomy procedures, namely the Nanoplasty® 3D Minimally Invasive Bunion Correction System and the Percuplasty™ Percutaneous 3D Bunion Correction System, and the SpeedMTP® MTP Fusion System. Treace continues to expand its footprint in the marketplace by extending its SpeedPlate® rapid compression implant platform to new applications, as well as providing surgeons with advanced digital solutions with its IntelliGuide™ patient specific, pre-op planning and cut guide technology. For more information, please visit www.treace.com.
To learn more about Treace, connect with us on LinkedIn, X, Facebook and Instagram.
Contacts:
Treace Medical Concepts
Mark L. Hair
Chief Financial Officer
mhair@treace.net
(904) 373-5940
Investors:
Gilmartin Group
Philip Trip Taylor
IR@treace.net
